BEST AVAILABLE COPY

AMENDMENT TO THE CLAIMS

Claims 1-19 (Cancelled)

- 20. (Currently Amended) An isolated nucleic acid of at least 12 contiguous nucleotides in length selected from the group consisting of from (a) a nucleic acid consisting of SEQ ID NO:1; (b) a nucleic acid consisting of SEQ ID NO:4; or the (c) a nucleic acid complementary sequences of to SEQ ID NO:1, or and (d) a nucleic acid complementary to SEQ ID NO:4; wherein said isolated nucleic acid of (a), (b), (c), or (d) is capable of specifically binding to the complement of the polynucleotide of SEQ ID NO:1; the complement of the polynucleotide of SEQ ID NO:4, respectively.
- 21. (Previously Amended) The nucleic acid of claim 20 which is 12 to about 75 contiguous nucleotides in length.
- 22. (Previously Amended) The nucleic acid of claim 20 which is 12 to 14 nucleotides in length.
- 23. (Previously Amended) The nucleic acid of claim 20 which is 14 to 18 nucleotides in length.
- 24. (Previously Amended) The nucleic acid of claim 20 which is 18 to 20 nucleotides in length.
- 25. (Previously Amended) The nucleic acid of claim 20 which is 20 to about 75 nucleotides in length.
- 26. (Previously Amended) The nucleic acid of claim 20 labeled with a radioactive, fluorescent, enzymatic, or chromogenic marker.
- 27. (Previously Amended) The nucleic acid of claim 20 wherein the nucleic acid is DNA.
- 28. (Currently Amended) The nucleic acid of claim 27 selected from the group consisting of (a) a nucleic acid consisting of SEQ ID NO:95; (b) a nucleic acid consisting of SEQ ID NO:105; (c) a nucleic acid consisting of SEQ ID NO:11, and the complementary sequences of; (d) a nucleic acid complementary to SEQ ID NO:95; (e) a nucleic acid complementary to SEQ ID NO:105; and of (f) a nucleic acid complementary to SEQ ID NO:11.
- 29. (Previously Presented) The nucleic acid of claim 27 selected from the group consisting of SEQ ID NO:9, SEQ ID NO:10, and SEQ ID NO:11.

30. (Previously Amended) A composition comprising the nucleic acid of claim 20 and a diluent or carrier.

Claims 31-33 (Cancelled)

- 34. (Currently Amended) The nucleic acid of claim 20 wherein the nucleic acid is DNA, or RNA, or any combination thereof.
- 35. (Previously Presented) The nucleic acid of claim 20 where the nucleic is RNA.

Claims 36-40 (Cancelled)

- 41. (Previously Presented) An oligonucleotide of at least 14 nucleotides in length capable of hybridizing, under conditions of moderate stringency, to a nucleic acid which encodes a polypeptide comprising SEQ ID NO:3 or SEQ ID NO:6.
- 42. (Previously Presented) The oligonucleotide of claim 41 which is DNA or RNA.
 - 43. (Previously Presented) The oligonucleotide of claim 41 which is DNA.
 - 44. (Previously Presented) The oligonucleotide of claim 41 which is RNA.
- 45. (Previously Presented) A composition comprising the oligonucleotide of claim 41 and a pharmaceutically acceptable diluent or carrier.